RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00432-019-02958-4.pdf
Reference19 articles.
1. Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T et al (2017) The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Rev Hematol. 10(6):575–582
2. Das D, Tian Z, Ray A, Ravillah D, Song Y, Richardson P, Oronsky B, Scicinski J, Chauhan D, Anderson K (2014) Anti-myeloma activity of a novel free radical inducer RRx-001. Blood 124(21):4712
3. Das DS, Ray A, Das A et al (2016) A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia 30(11):2187–2197. https://doi.org/10.1038/leu.2016.96
4. Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62(7):919–930
5. Grossman R, Ram Z (2013) The dark side of Nrf2. World Neurosurg. 80(3–4):284–286. https://doi.org/10.1016/j.wneu.2011.09.055 (Epub 2012 Dec 12)
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy;International Journal of Radiation Oncology*Biology*Physics;2023-07
2. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist;Frontiers in Oncology;2023-05-29
3. Radiation and Diabetic Retinopathy: A Dark Synergy;International Journal of Translational Medicine;2023-03-07
4. High-throughput screening strategies for space-based radiation countermeasure discovery;Life Sciences in Space Research;2022-11
5. Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway;Pharmacological Research;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3